Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
1.
Rev. bras. neurol ; 57(4): 5-8, out.-dez. 2021. tab
Article in English | LILACS | ID: biblio-1359194

ABSTRACT

BACKGROUND: Myasthenia gravis (MG) is an autoimmune disease marked by fluctuating course of muscle weakness. OBJECTIVES: The current study was designed to evaluate plasma levels of cytokines (IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, and IL17A) in patients with MG and controls and to investigate whether cytokines levels are associated with clinical parameters. This study was conducted at the Neuromuscular Diseases Outpatient Clinic, Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG), Brazil. METHODS: Peripheral blood was drawn, and plasma levels of cytokines were measured by cytometric bead array (CBA) in 80 treated patients with MG and 50 controls. The MG Composite (MGC) was used to evaluate muscle weakness and severity of typical motor symptoms of MG. RESULTS: Patients with MG undergoing treatment exhibit lower levels of all evaluated cytokines compared to controls. There was a negative correlation between IL-6 levels and the MG Composite score, indicating that higher levels of IL-6 were associated with better control of the disease. CONCLUSION: This exploratory study suggests that IL-6 is associated with MG clinical status, as assessed by the MGC.


INTRODUÇÃO: A Miastenia Gravis (MG) é uma doença autoimune caracterizada por fraqueza muscular flutuante. OBJETIVOS: avaliar os níveis plasmáticos de citocinas (IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, e IL-17A) em pacientes com MG e controles e investigar se essas citocinas estão associadas com parâmetros clínicos. Este estudo foi conduzido no ambulatório de doenças neuromusculares do Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG), Brasil. MÉTODOS: Foi coletado sangue periféricos e os níveis plasmáticos das citocinas foram medidos por citometria em 80 pacientes com MG tratados e em 50 controles. O MG composite (MGC) foi utilizado para avaliar a fraqueza muscular e a gravidade dos sintomas motores típicos da MG. RESULTADOS: Os pacientes com MG em tratamento apresentaram menores níveis de todas as citocinas avaliadas comparados ao controle. Houve uma correlação negativa entre os níveis de IL-6 e o MGC, indicando que altos níveis de IL-6 estão associados com melhor controle da doença. CONCLUSÃO: este estudo exploratório sugere que a IL-6 está associada com o status clínico da MG, quando avaliado pelo MGC.


Subject(s)
Humans , Male , Female , Adult , Cytokines/blood , Interleukin-6 , Myasthenia Gravis/diagnosis , Myasthenia Gravis/immunology , Myasthenia Gravis/drug therapy , Prednisone/therapeutic use , Blood Specimen Collection , Muscle Weakness
2.
Brasil; CONITEC; abr. 2021.
Non-conventional in Portuguese | LILACS, ColecionaSUS | ID: biblio-1378092

ABSTRACT

CONTEXTO: Os PCDT são documentos que visam garantir o melhor cuidado de saúde diante do contexto brasileiro e dos recursos disponíveis no SUS. Podem ser utilizados como materiais educativos aos profissionais de saúde, auxílio administrativo aos gestores, regulamentação da conduta assistencial perante o Poder Judiciário e explicitação de direitos aos usuários do SUS. Os PCDT são os documentos oficiais do SUS que estabelecem critérios para o diagnóstico de uma doença ou agravo à saúde; tratamento preconizado, com os medicamentos e demais produtos apropriados, quando couber; posologias recomendadas; mecanismos de controle clínico; e acompanhamento e verificação dos resultados terapêuticos a serem seguidos pelos gestores do SUS. Os PCDT devem incluir recomendações de condutas, medicamentos ou produtos para as diferentes fases evolutivas da doença ou do agravo à saúde de que se tratam, bem como aqueles indicados em casos de perda de eficácia e de surgimento de intolerância ou reação adversa relevante, provocadas pelo medicamento, produto ou procedimento de primeira escolha. A lei reforçou a análise baseada em evidências científicas para a elaboração dos protocolos, destacando os critérios de eficácia, segurança, efetividade e custo-efetividade para a formulação das recomendações sobre intervenções em saúde. Para a constituição ou alteração dos PCDT, a Portaria GM n° 2.009 de 2012 instituiu na Conitec uma Subcomissão Técnica de Avaliação de PCDT, com as competências de definir os temas para novos protocolos, acompanhar sua elaboração, avaliar as recomendações propostas e as evidências científicas apresentadas, além da revisão periódica dos PCDT vigentes, em até dois anos. A Subcomissão Técnica de Avaliação de PCDT é composta por representantes de Secretarias do Ministério da Saúde interessadas na elaboração de diretrizes clínicas: Secretaria de Atenção Primária à Saúde, Secretaria de Atenção Especializada à Saúde, Secretaria de Vigilância em Saúde, Secretaria Especial de Saúde Indígena e Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Após concluídas as etapas de definição do tema e escopo do PCDT, de busca, seleção e análise de evidências científicas e consequente definição das recomendações, a aprovação do texto é submetida à apreciação do Plenário da Conitec, com posterior disponibilização deste documento para contribuição de sociedade, por meio de consulta pública (CP) pelo prazo de 20 dias, antes da deliberação final e publicação. A consulta pública é uma importante etapa de revisão externa dos PCDT. O Plenário da Conitec é o fórum responsável pelas recomendações sobre a constituição ou alteração de PCDT, além dos assuntos relativos à incorporação, exclusão ou alteração das tecnologias no âmbito do SUS, bem como sobre a atualização da Relação Nacional de Medicamentos Essenciais (RENAME). É composto por treze membros, um representante de cada Secretaria do Ministério da Saúde ­ sendo o indicado pela Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde (SCTIE) o presidente do Plenário ­ e um representante de cada uma das seguintes instituições: ANVISA, Agência Nacional de Saúde Suplementar - ANS, Conselho Nacional de Saúde - CNS, Conselho Nacional de Secretários de Saúde - CONASS, Conselho Nacional de Secretarias Municipais de Saúde - CONASEMS e Conselho Federal de Medicina - CFM. Cabe à Secretaria-Executiva, exercida pelo Departamento de Gestão e Incorporação de Tecnologias e Inovação em Saúde (DGITIS/SCTIE), a gestão e a coordenação das atividades da Conitec. Conforme o Decreto n° 7.646 de 2011, o Secretário de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde deverá submeter o PCDT à manifestação do titular da Secretaria responsável pelo programa ou ação a ele relacionado antes da sua publicação e disponibilização à sociedade. APRESENTAÇÃO: A proposta de atualização do PCDT de Miastenia Gravis é uma demanda que cumpre o Decreto nº 7.508 de 28 de junho de 2011 e as orientações previstas no artigo 26º e o parágrafo único, sobre a responsabilidade do Ministério da Saúde de atualizar os Protocolos Clínicos e Diretrizes Terapêuticas. Este PCDT apresenta a atualização da versão publicada em 2015, com inclusão do exame complementar de diagnóstico dosagem sérica de anticorpos de acetilcolina (anti-AChR). DELIBERAÇÃO INICIAL: Os membros da Conitec presentes na 88ª Reunião do Plenário, realizada nos dias 07, 08 e 09 de julho de 2020, deliberaram para que o tema fosse submetido à consulta pública com recomendação preliminar favorável à publicação deste Protocolo. CONSULTA PÚBLICA: A Consulta Pública nº 27/2020 foi realizada entre os dias 21 de julho a 10 de agosto de 2020. A seguir é apresentado o resumo da análise das contribuições recebidas, ressaltando-se que foram consideradas apenas as encaminhadas no período estipulado e por meio do sítio eletrônico da Conitec. Os dadosforam avaliados quantitativa e qualitativamente, considerando asseguintes etapas: a) leitura de todas as contribuições, b) identificação e categorização das ideias centrais, e c) discussão acerca das contribuições. Foram recebidas ao todo 34 contribuições. A grande maioria dos participantes (n= 33; 97%) classificou a proposta de PCDT como boa ou muito boa na avaliação geral.


Subject(s)
Clinical Protocols/standards , Myasthenia Gravis/diagnosis , Myasthenia Gravis/drug therapy , Thymectomy/instrumentation , Unified Health System , Brazil , Immunoglobulins/therapeutic use , Acetylcholine/blood , Cholinesterase Inhibitors/therapeutic use , Plasmapheresis/instrumentation , Diagnosis, Differential , Electric Stimulation/methods , Immunosuppressive Agents/therapeutic use
3.
Rev. méd. Chile ; 148(7): 1031-1033, jul. 2020.
Article in Spanish | LILACS | ID: biblio-1139406

ABSTRACT

Myasthenia gravis (MG) is a heterogeneous disease, and there is no unique therapeutic approach for all patients. In 2013 the Myasthenia Gravis American Foundation (MGFA) panel of experts defined refractory MG as the lack of change or deterioration after the use of corticosteroids and two immunosuppressive agents, in adequate doses and time. We report a 51-years-old female with MG of bulbar predominance, who presented four myasthenic crises in 17 months despite the use of corticosteroids, azathioprine and mycophenolate. The high costs associated with her hospitalizations, as well as severe caloric - protein malnutrition, the need for tracheostomy and gastrostomy support, led us to use rituximab. The patient evolved with an excellent response, free of crises after 30 months. She gained 12 kg of weight, without tracheostomy and gastrostomy, only using pyridostigmine support 4 times a day.


Subject(s)
Humans , Female , Middle Aged , Rituximab/therapeutic use , Myasthenia Gravis/drug therapy , Immunologic Factors/therapeutic use , Myasthenia Gravis/diagnosis
4.
Arq. neuropsiquiatr ; 78(3): 179-181, Mar. 2020. tab
Article in English | LILACS | ID: biblio-1098074

ABSTRACT

Abstract Currently, pyridostigmine bromide is an indispensable anticholinesterase agent used worldwide to treat patients with Myasthenia Gravis (MG). However, pyridostigmine bromide was unsuccessful in its "pioneering trials" to treat a series of MG patients. There are important historical landmarks before pyridostigmine bromide becomes useful, safe and indispensable for MG therapy. After 70 years of these "pioneering trials", this article reviews some historical aspects related to them, as well as other preliminary trials using pyridostigmine bromide as therapy for MG patients.


Resumo Atualmente, o brometo de piridostigmina é um indispensável agente anticolinesterásico usado em todo o mundo no tratamento de pacientes com Miastenia Gravis (MG). Contudo, o brometo de piridostigmina não foi bem-sucedido, em seus "ensaios clínicos pioneiros", no tratamento de uma série de pacientes com MG. Existem importantes marcos históricos antes do brometo de piridostigmina se tornar útil, seguro e indispensável no tratamento da MG. Após 70 anos desses "ensaios clínicos pioneiros", este artigo revisa alguns aspectos históricos a eles relacionados, bem como a outros estudos preliminares que usaram o brometo de piridostigmina como um tratamento para pacientes com MG.


Subject(s)
Humans , Pyridostigmine Bromide/therapeutic use , Cholinesterase Inhibitors/therapeutic use , Myasthenia Gravis/drug therapy
5.
Rev. méd. Maule ; 34(2): 30-40, dic. 2019. tab
Article in Spanish | LILACS | ID: biblio-1371248

ABSTRACT

Myasthenia gravis is an acquired autoimmune disorder of the neuromuscular junction characterized by fluctuating weakness and fatigability of skeletal muscles. The diagnosis can be established by clinical and serologic testing, with predominance of autoantibodies against the acetylcholine receptor, and Muscle-specific kinase antibodies. We report two cases of Myasthenia gravis, the first one is a 31 year old patient with a debut of the disease, mainly with bulbar symptoms, and the second one is a 29 year old patient diagnosed with generalized Miasthenia Gravis also mainly with bulbar symptoms with worsening of symptomatology. In this report treatments alternatives and management approaches are discused


Subject(s)
Humans , Female , Adult , Myasthenia Gravis/immunology , Myasthenia Gravis/drug therapy , Pyridostigmine Bromide/therapeutic use , Thymectomy , Immunoglobulins, Intravenous/therapeutic use , Glucocorticoids/therapeutic use , Immunosuppressive Agents/therapeutic use , Immunotherapy , Myasthenia Gravis/surgery , Myasthenia Gravis/classification
6.
Medicina (B.Aires) ; 78(supl.2): 82-87, set. 2018. tab
Article in Spanish | LILACS | ID: biblio-955020

ABSTRACT

Las enfermedades autoinmunes del sistema nervioso periférico son frecuentes en pediatría. Las más importantes son el síndrome de Guillain-Barré, la miastenia gravis juvenil y la dermatomiositis juvenil. Tienen en común ser causadas por acción de anticuerpos específicos que producen la signología clínica, reacción que puede ser gatillada por un cuadro viral o bacteriano, como ocurre principalmente en SGB. La polineuropatía aguda inflamatoria desmielinizante es más frecuente. Existe también la forma axonal motora. Ambas tienen clínica progresiva ascendente. El tratamiento específico es la inmunoglobulina 2 g/ kg. La miastenia gravis juvenil se expresa por signos oculares, generalizados y fatigabilidad fluctuante. Puede comprometer la función respiratoria desencadenando crisis miasténica. Se trata con anticolinesterásicos, corticoides, inmunoglobulinas e inmunosupresores. La timectomía ha mostrado recientemente su efectividad. La dermatomiositis juvenil se expresa por signos cutáneos y musculares. Se diagnostica por elevación de enzimas musculares, biopsia y resonancia musculares y se trata con corticoides, inmunoglobulinas e inmunosupresores. Tanto el síndrome de Guiilain-Barré, como la miastenia gravis y la dermatomiositis juvenil, tienen buen pronóstico.


Autoimmune diseases of the peripheral nervous system are common in pediatrics. Guillain-Barré syndrome, juvenile myasthenia gravis, and juvenile dermatomyositis are the most important. Their common pathogenesis involves the action of specific autoantibodies which are frequently triggered by viral or bacterial infection. Acute inflammatory demyelinating polyneuropathy is the most frequent pathological feature. There is also a motor axonal form. Both have a progressive ascending clinical course. The specific treatment is immunoglobulin 2 g/kg. Juvenile myasthenia gravis is expressed by ocular signs and generalized and fluctuating fatigability. It can involve respiratory functions triggering a myasthenic crisis. It is treated with anticholinesterase agents, corticosteroids, immunoglobulins, and immunosuppressants. Thymectomy has recently shown effectiveness. Juvenile dermatomyositis is expressed by skin and muscle signs. Elevated muscle enzymes, muscle biopsy, and magnetic resonance imaging contribute to the diagnosis. It is treated with corticosteroids, immunoglobulins, and immunosuppressants. All three disorders, Guillain-Barré, juvenile myasthenia gravis, and juvenile dermatomyositis have a good prognosis.


Subject(s)
Humans , Guillain-Barre Syndrome/diagnosis , Dermatomyositis/diagnosis , Myasthenia Gravis/diagnosis , Prognosis , Immunoglobulins , Prednisone/therapeutic use , Cholinesterase Inhibitors/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Guillain-Barre Syndrome/drug therapy , Dermatomyositis/drug therapy , Myasthenia Gravis/drug therapy
7.
Rev. méd. Chile ; 145(12): 1626-1630, dic. 2017. graf
Article in Spanish | LILACS | ID: biblio-902489

ABSTRACT

Myasthenia gravis (MG) is a rare autoimmune disease of the neuromuscular junction. It is characterized by variable weakness and excessive fatigability of skeletal muscles. In the last few years, numerous reports have been published showing the association between autoimmune diseases, such as systemic erythematous lupus or rheumatoid arthritis, with lymphoid neoplasias. The association between MG and lymphoid neoplasia seems to be less frequent. To analyze this association we reviewed the MG patients in the Department of Neurology, Hospital Salvador of Santiago, Chile. During a three-year period we identified four patients who developed different lymphoproliferative disorders: two with B-cell lymphoma, one with chronic lymphocytic leukaemia and one plasmacytoma with an associated amyloidosis. The MG was generalized but mild, all cases classified as type IIa according to the definition proposed by the MG Foundation of America. The neoplasia appeared two to 36 years after the onset of MG. These cases provide additional evidence of the association between MG and lymphoproliferative disorders.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Plasmacytoma/complications , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Lymphoma, Large B-Cell, Diffuse/complications , Myasthenia Gravis/complications , Plasmacytoma/pathology , Pyridostigmine Bromide/therapeutic use , Biopsy , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Cholinesterase Inhibitors/therapeutic use , Lymphoma, Large B-Cell, Diffuse/pathology , Fatal Outcome , Amyloidosis/complications , Amyloidosis/pathology , Myasthenia Gravis/pathology , Myasthenia Gravis/drug therapy
8.
Arq. neuropsiquiatr ; 75(11): 825-826, Nov. 2017. graf
Article in English | LILACS | ID: biblio-888270

ABSTRACT

ABSTRACT Mary Broadfoot Walker was a Scottish physician who, in 1935, described in great detail the effect of an anticholinesterase drug (physostigmine) on the signs and symptoms of myasthenia gravis. An original five-minutes movie is available online and the skepticism of her contemporary British medical doctors is understandable when the drastic effect of the treatment is shown in this movie. What Mary Walker taught us, more than eight decades ago, about myasthenia gravis continues to be the basis of a pharmacological diagnostic test and treatment of this disease.


RESUMO Mary Broadfoot Walker foi uma médica escocesa que em 1935 descreveu em grande detalhe o efeito de uma droga anticolinesterásica (fisostigmina) nos sinais e sintomas da myasthenia gravis. Um filme original com cinco minutos de duração está disponível online e a reação cética dos colegas médicos contemporâneos de Mary é compreensível dado o drástico efeito terapêutico mostrado neste filme. O que Mary Walker nos ensinou mais de oito décadas atrás continua a ser a base de um teste diagnóstico farmacológico e do tratamento da myasthenia gravis.


Subject(s)
History, 20th Century , Physostigmine/history , Cholinesterase Inhibitors/history , Myasthenia Gravis/history , Physostigmine/therapeutic use , Scotland , Video Recording , Cholinesterase Inhibitors/therapeutic use , Myasthenia Gravis/drug therapy
10.
Rev. medica electron ; 39(2): 338-345, mar.-abr. 2017.
Article in Spanish | LILACS, CUMED | ID: biblio-845405

ABSTRACT

La miastenia grave es una enfermedad autoinmune de la placa motora del músculo estriado, caracterizada por fatiga y debilidad muscular fluctuante. La prevalencia es aproximadamente de 5 casos por cada 100 000 personas. La paciente reportada presentó síntomas que limitaban la musculatura cercana al ojo. Esta entidad se denomina miastenia grave ocular, su incidencia en el embarazo es infrecuente. Se reportó un caso de una paciente de 23 años de edad, atendida en la Consulta de Infertilidad del municipio Isla de la Juventud. Se consultó el caso con varias especialidades médicas. El nacimiento se produjo por cesárea de urgencia producto de estado fetal intranquilizante y aplicando anestesia regional. Se obtiene bebé sano, con buena puntuación de apgar y buen peso. Durante el puerperio la madre y el recién nacido evolucionaron satisfactoriamente (AU).


Myasthenia gravis is an autoimmune disease of the motor end-plate of the striated muscle, characterized by fluctuant muscular fatigue and weakness. Its prevalence is around 5 cases per 100 000 persons. The reported patient presented symptoms limiting the muscles near the eye. This entity is named ocular myasthenia gravis. Its incidence in pregnancy is infrequent. It is reported the case of a female patient, aged 23 years, attended in the Infertility Consultation of the municipality Isla de la Juventud. The case was consulted with several medical specialties. The delivery was produced by emergency cesarean section, applying regional anesthesia, due to the worrying fetal status. The newborn had good apgar score and weight. Mother and child showed satisfactory evolution during the postpartum period (AU).


Subject(s)
Humans , Female , Young Adult , Pregnant Women , Myasthenia Gravis/complications , Myasthenia Gravis/diagnosis , Myasthenia Gravis/drug therapy , Myasthenia Gravis/epidemiology , Prenatal Care/methods , Prenatal Care/standards , Signs and Symptoms
13.
Rev. chil. endocrinol. diabetes ; 4(4): 257-260, oct. 2011. tab
Article in Spanish | LILACS | ID: lil-640608

ABSTRACT

Myasthenia gravis and Graves disease are autoimmune diseases that can coexist in the same patient. We report a 18 years old female with a history of myasthenia gravis diagnosed at the age of six, treated with neostigmine and prednisone. She starts with palpitations, dyspnea, proximal muscle weakness and exophthalmos appearing seven months after the onset of symptoms. She was admitted to the hospital due to her decompensated hyperthyroidism. After admission, she develops a myasthenic crisis, that requires mechanical ventilation. Afterwards, the patient is subjected to a thymectomy and thyroidectomy with a good postoperative evolution.


Subject(s)
Humans , Adolescent , Female , Graves Disease/complications , Myasthenia Gravis/complications , Graves Disease/surgery , Graves Disease/drug therapy , Myasthenia Gravis/surgery , Myasthenia Gravis/drug therapy , Thymectomy , Thyroidectomy , Treatment Outcome
14.
Rev. cuba. med. gen. integr ; 24(2)abr.-jun. 2008.
Article in Spanish | LILACS | ID: lil-505319

ABSTRACT

En este trabajo se presenta a un adolescente masculino que inició un cuadro de fatigabilidad muscular tras el ejercicio, que lo llevó a desaprobar la asignatura de preparación física. Posteriormente comienza a presentar dificultades para ingerir alimentos, para pronunciar palabras y asimetría en la fuerza muscular de ambos hemicuerpos. Es ingresado, y a los pocos días comienza a presentar alteraciones respiratorias, por lo que se decide su traslado a la sala de cuidados intensivos donde fue necesario acoplarlo a un ventilador mecánico. En esta oportunidad no hubo respuesta a la administración de anticolinesterásicos, sin embargo comenzó a mejorar con el tratamiento con esteroides. Evolucionó satisfactoriamente con recuperación lenta y progresiva de la fuerza muscular. Se restableció el tratamiento con anticolinesterásicos paulatinamente con buena respuesta en esta oportunidad.


A male adolescent that started with a picture of muscle weakness after doing exercises that led him to fail the physical education subject is presented in this paper. Later on, he began to have difficulties to eat and to pronounce words, and to show asymmetry in the muscular strength of both hemibodies. He was admitted and a few days after he had respiratory alterations and it was decided to transfer him to an intensive care unit and to couple him to a mechanical ventilator. In that opportunity, there was no response to the administration of anticholinesterase agents; however, he began to improve with steroids. His evolution was satisfactory with a slow and progressive recovery of the muscle strength. The treatment with anticholinesterase agents was gradually re-established with a good response this time.


Subject(s)
Humans , Male , Adolescent , Anti-Bacterial Agents/therapeutic use , Steroids/therapeutic use , Myasthenia Gravis/physiopathology , Myasthenia Gravis/drug therapy , Case Reports
15.
Article in English | IMSEAR | ID: sea-85196

ABSTRACT

Myasthenia gravis is an autoimmune disorder where antibodies against the nicotinic Ach receptor resulting in impaired transmission at the NM junction. A number of drugs have been reported to cause neuromuscular blockade and/or to increase weakness in myasthenia gravis. We report a case of myasthenia gravis in which the calcium channel blocker-nifedipine caused the worsening of the symptoms.


Subject(s)
Adult , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Calcium Channel Blockers/adverse effects , Humans , Male , Myasthenia Gravis/drug therapy , Nifedipine/adverse effects
16.
Article in English | IMSEAR | ID: sea-45479

ABSTRACT

Myasthenia gravis and hypokalemic periodic paralysis are commonly related with hyperthyroidism but rarely occur together. Here, the authors reported a case of hypokalemic periodic paralysis in a Northeastern Thai woman accompanied with myasthenia gravis. She had motor weakness despite a normal level of serum potassium. Prostigmine test was positive. She dramatically improved after pyridostigmine treatment. Autoantibodies to nicotinic AchR-Ab and dihydropyridine receptor or L-type voltage gated calcium channel were postulated to explain these associated diseases.


Subject(s)
Adult , Cholinesterase Inhibitors/therapeutic use , Female , Humans , Hypokalemic Periodic Paralysis/physiopathology , Myasthenia Gravis/drug therapy , Pyridostigmine Bromide/therapeutic use , Thailand
18.
Oman Medical Journal. 2004; 19 (2): 58-9
in English | IMEMR | ID: emr-67958

ABSTRACT

Myasthenia gravis most commonly affects young adult women and older men. Juvenile myasthenia gravis is considered to be a variant of adult myasthenia, and it comprises approximately 1% of all cases of myasthenia gravis. This report describes a ten-year old girl with drooping of eyelids since one year


Subject(s)
Humans , Female , Myasthenia Gravis/drug therapy , Pyridostigmine Bromide , Receptors, Cholinergic , Cholinergic Antagonists
19.
J Postgrad Med ; 2003 Oct-Dec; 49(4): 311-4; discussion 314-5
Article in English | IMSEAR | ID: sea-115400

ABSTRACT

CONTEXT: Patients with myasthenia gravis receive pyridostigmine, an anticholinesterase agent, as a part of therapy. These patients demonstrate a heightened sensitivity towards non-depolarising muscle relaxants. Continuing pyridostigmine till the day of the surgery or omitting it on the night before surgery could provide variable results with regards to the effect of vecuronium. AIMS: Myographic evaluation of a dose of vecuronium in patients with myasthenia gravis on pyridostigmine therapy. SETTING AND DESIGN: A randomised, double-blind, clinical study conducted in a teaching hospital. SUBJECTS AND METHODS: Medically (oral pyridostigmine) well-controlled adult patients with myasthenia gravis who were posted for thymectomy, were randomly divided into two groups. Patients in Group 1 received their last dose of pyridostigmine on the night before surgery while those in Group 2 received even the morning dose of the drug on the day of surgery. Neostigmine (1-2 mg) intravenously was used as rescue medication. Vecuronium (0.01 mg/kg) was used for intubation and muscle relaxation during trans-sternal thymectomy and its effect was reversed using neostigmine and atropine. RESULTS: Fourteen patients (7 in each group) belonging to both sexes were enrolled in the study. The intubating dose of vecuronium showed quicker onset time (155 sec or 2.7 min approx.) and peak effect (99% T1 suppression) in patients belonging to Group 1, and 3/7 (43%) complained of respiratory discomfort while waiting for surgery. By giving the morning dose of pyridostigmine (Group 2), an identical intubating dose of vecuronium showed relative resistance (peak effect-97% T1 suppression) and delayed onset time (198 sec approx.). However, the reversal was complete at the end of surgery in both the regimens. CONCLUSIONS: Omission of the pyridostigmine dose on the day of surgery predisposed patients with myasthenia gravis to the possibility of respiratory discomfort and sensitivity to vecuronium. Continued administration significantly prolonged the onset time of vecuronium and the patients required a higher dose of vecuronium.


Subject(s)
Adult , Cholinesterase Inhibitors/therapeutic use , Female , Humans , Male , Myasthenia Gravis/drug therapy , Neuromuscular Nondepolarizing Agents/administration & dosage , Pyridostigmine Bromide/therapeutic use , Vecuronium Bromide/administration & dosage
20.
Rev. cuba. cir ; 42(3)jul.-sept. 2003. tab
Article in Spanish | LILACS, CUMED | ID: lil-360490

ABSTRACT

Se reporta un estudio de cohorte analítico para evaluar factores pronósticos en 34 pacientes con timoma y miastenia gravis, a los cuales se les realizó timectomía, entre enero de 1984 y diciembre de 1998, 22 femeninos y 12 masculinos, con un promedio de edad de 49,7 años. De acuerdo con la clasificación clínica de Masaoka, 14 pertenecieron al estadio I, 2 al II, 12 al III y 6 al IV. Histológicamente 17 fueron mixtos, 9 corticales, 5 medulares y 3 carcinomas tímicos bien diferenciados. Según la clasificación de Osserman 5 enfermos se encontraban en el grupo IIa, 23 en el IIb y 6 en el IV. La vía de acceso fue la esternotomía media. Los pacientes con tumores invasivos recibieron radioterapia y poliquimioterapia adyuvante. El índice de remisión de los síntomas miasténicos al año fue de 53,1 (por ciento). Hubo 3 fallecidos en el período posoperatorio y 7 tardíamente. El timoma cortical y, en general, los tumores invasivos fueron los de peores resultados. Los factores que más se relacionaron con el pronóstico por su influencia sobre el intervalo libre de enfermedad y la supervivencia a largo plazo, fueron el estadio clínico del tumor, el tipo hístico y el tipo de miastenia.


This paper presents an analytical cohort study to evaluate prognostic factors in 34 patients with thymona and myasthemia gravis whom thymectomy from January 1984 to December 1998. Twenty two were females and 12 males aged 49,7 years of age as average. According to Masaoka´s clinical classification, 14 patients were at stage I; two at stage II, 12 at stage III and 6 at stage IV. From the histological viewpoint, 17 were mixed thymona, 9 cortical thymonas, 5 medullar thymonas and 3 well-differentiated thymic carcinomas. According to Osswerman´s classification, 5 patients were included in group IIa, 23 in group IIb and 6 in group IV. The access pathway was median sternotomy. Remission index of myasthemic symptoms after a year was 53.1 percent. there were 3 deaths in the postoperative period and 7 died later. Cortical thymona and in general, invasive tumors showed the worst results. The most related factors to prognosis because of their influence over the disease-free interval and the long term survival were the clinical staging of tumor, the hystic type and the type of myasthemia(AU)


Subject(s)
Humans , Male , Female , Adult , Thymectomy/methods , Thymoma/surgery , Thymus Neoplasms/diagnosis , Myasthenia Gravis/drug therapy , Cohort Studies , Survivorship
SELECTION OF CITATIONS
SEARCH DETAIL